SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) |
12 Months Ended | |||
|---|---|---|---|---|
Dec. 31, 2025 |
Dec. 31, 2024 |
Mar. 01, 2024 |
Jan. 17, 2019 |
|
| Allowance for doubtful accounts | $ 0 | $ 0 | ||
| Advertising costs | 65,241 | 33,506 | ||
| Grant funding during the first year | $ 4,131,123 | $ 2,842,430 | ||
| Grant funding | 11,029,977 | |||
| Grant funding during the second year | 3,638,268 | 2,831,838 | ||
| Grant funding during the third year | $ 3,260,586 | 3,453,367 | ||
| Grant additional funding during the third year | $ 99,431 | |||
| Grant receivables | 52,026 | 0 | ||
| Deferred revenues related to grant | 0 | 56,590 | ||
| Grant income | 2,435,848 | 1,473,276 | ||
| Research and development expenses | $ 1,768,955 | $ 1,482,877 | ||
| Ownership percentage | 50.00% | |||
| Royalty obligations description | The Company accounted for royalty obligations as debt in accordance with ASC 470-10-25 and derived a debt discount, which is amortized using the straight line method over the expected life of the arrangement, which is 15 years. The Company has no obligation to repay the then outstanding balance if during the expected life of 15 years the treatment is discontinued | |||
| Description of Non-Controlling Interest | Due to a management fee equal to 65% of the Medical Corporation’s gross collected monthly revenue, 65% of the Medical Corporation’s earnings was allocated to the Company, and 35% to the non-controlling interest. Due to the Company’s retaining 75.8% ownership of BioCorRx Pharmaceuticals, Inc., 75.8% of BioCorRx Pharmaceuticals, Inc.’s earnings was allocated to the Company, and 24.2% to the non-controlling interest | |||
| Royalty obligations, net | $ 7,171,200 | |||
| Minimum [Member] | ||||
| Property plant and equipment estimated useful lives | 5 years | |||
| Maximum [Member] | ||||
| Property plant and equipment estimated useful lives | 15 years | |||